International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractor y acute lymphoblastic leukemia

Haematologica

Volumn 101, Issue 12, 2016, Pages 1524-1533

  Gökbuget, Nicola ^a   Dombret, Hervè ^b   Ribera, Jose Maria ^c   Fielding, Adele K ^d   Advani, Anjali ^e   Bassan, Renato ^f   Chia, Victoria ^g   Doubek, Michael ^h   Giebel, Sebastian ⁱ   Hoelzer, Dieter ^a   Ifrah, Norbert ^j   Katz, Aaron ^g   Kelsh, Michael ^g   Martinelli, Giovanni ^k   Morgades, Mireia ^c   O’Brien, Susan ^l   Rowe, Jacob M ^m   Stieglmaier, Julia ⁿ   Wadleigh, Martha ^o   Kantarjian, Hagop ^l  

^a GOETHE UNIVERSITY   (Germany)

^b SAINT LOUIS HOSPITAL   (France)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LERNER RESEARCH INSTITUTE   (United States)

^f OSPEDALE DELL'ANGELO   (Italy)

^g AMGEN INC   (United States)

^h UNIVERSITY HOSPITAL BRNO   (Czech Republic)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j ANGERS UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l UNIVERSITY OF TEXAS   (United States)

^m RAMBAM MEDICAL CENTER   (Israel)

ⁿ Novartis Pharma   (Germany)

^o DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DEMOGRAPHY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRE B LYMPHOCYTE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY ANALYSIS; STEM CELL TRANSPLANTATION; YOUNG ADULT; CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; HEALTH CARE SURVEY; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHILADELPHIA 1 CHROMOSOME; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENT DISEASE; REMISSION; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85002157898     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.144311     Document Type: Article

References (23)

1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543.
2. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950.
3. Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041.
4. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186-3191.
5. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589-596.
6. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914.
7. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116(24):5568-5574.
8. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013; 14(6):e205-217.
9. Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25(6):701-706.
10. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer. cancer. gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
11. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136-5142.
12. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006; 24(12):1917-1923.
13. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100(6):1965-1971.
14. Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140.
15. Brookmeyer R, Crowley J. A. K-sample median test for censored data. J Am Statistical Assoc. 1982;77:433-440.
16. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley and Sons, New York, 1980.
17. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus nonresponder bias. Stat Med. 1984;3(1):35-44.
18. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216-1230.
19. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3407-3415.
20. Choi S, Henderson MJ, Kwan E, et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood. 2007;110(2):632-639.
21. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13(4):403-411.
22. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371 (16):1507-1517.
23. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory Bprecursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1): 57-66.